Compare Amphastar Pharmaceuticals Inc (AMPH) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Solaredge Technologies Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Solaredge Technologies Inc trades at $54.59 (market cap $3.36B). The key difference: Solaredge Technologies Inc is far larger — about 4.1× Amphastar Pharmaceuticals Inc's market cap, and Solaredge Technologies Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | SEDG | |
|---|---|---|
Market Cap | $826.08M | $3.36B |
Sector | Health | Technology |
52-Week High | $30.81 | $78.51 |
52-Week Low | $16.87 | $24.42 |
Enterprise Value | $1.22B | $3.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
SolarEdge Technologies (SEDG) trades at $55.18, up 0.77% on the day, with a neutral technical signal and mixed analyst sentiment. The company shows improving operational cash flow ($104M in 2025) but continues to report significant losses (-$405M net income). Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, while solar sector momentum from AI data center demand provides tailwinds.
The stock faces fundamental challenges with negative margins and high debt, though cash flow stabilization and sector growth offer potential upside. Key risks include persistent profitability issues and policy uncertainty, while analyst consensus remains cautious with a $34.99 price target below current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
